Supply Chain Action Points
Read this first — the conclusion, and the moves to make:
- By 1 July 2026, build a dated watch list with three tracks, the 18-partner 301 hearings led by the 22 September Germany pharma date, the 24 July Section 122 expiry and its refund implications, and the China port-fee proposal with its unknown date flagged as the highest-uncertainty item. Owner is your trade compliance lead.
- By 8 July 2026, quantify your refund exposure tied to the Section 122 10 percent surcharge before the 24 July expiry, line by line, because once the rate lapses the restacking mechanics have to be settled and unclaimed refunds become harder to recover.
- By 15 July 2026, if you move bulk or agricultural outbound freight, model the China port fee as a per-vessel charge passed into your cargo and estimate the per-ton impact on your export lanes, since the cost lands on low-value bulk regardless of product origin.
- By 22 July 2026, confirm with your forwarder and customs broker which entries would be affected if the Section 122 surcharge is not extended, and document the替代 tariff structure you would default to, so a lapsed rate does not leave entries unpriced.
- By 15 September 2026, submit or join comments on the Germany pharma probe ahead of the 22 September hearing, with your specific API or finished-dose exposure itemized, because that lane is slow but it is the one with a fixed date you can still influence.
The Office of the U.S. Trade Representative opened public hearings on its expanded Section 301 investigations, with the first wave covering 18 trading partners across pharmaceuticals, automobiles, semiconductors, and steel. The Germany pharma probe — first announced June 22 — is set for a Sept 22 hearing. The USTR simultaneously floated new Section 301 China port fees targeting Chinese-built vessels, drawing a sharp letter from the Agriculture Transportation Coalition warning of “immediate and severe” impacts on U.S. agricultural exports. The Section 122 global 10% surcharge expires July 24 unless Congress extends it, putting a hard deadline on refund logistics and tariff restacking.
The Analysis
The Office of the U.S. Trade Representative has opened public hearings on an expanded set of Section 301 investigations, and the first wave names 18 trading partners across pharmaceuticals, automobiles, semiconductors, and steel. The Germany pharmaceutical probe, first announced 22 June, is set for a 22 September hearing. At the same time USTR floated new Section 301 fees on Chinese-built vessels, and the Agriculture Transportation Coalition wrote a sharp letter warning of immediate and severe harm to U.S. agricultural exports.
The dates matter more than the sector list. The Section 122 global 10 percent surcharge expires 24 July unless Congress extends it, and that expiry puts a hard deadline on refund logistics and on any tariff restacking you might be planning. Two clock speeds are running at once here, and only one of them is loud.
Start with the hard structure, because the sectors are a distraction from the schedule. Eighteen trading partners are in the first wave. Four sectors are named: pharma, autos, semiconductors, steel. The Germany pharma probe has a 22 September hearing date. That is the only fixed date in the pharma lane, and it is months out, which means the pharma exposure is a planning problem, not a this-quarter problem. The mistake is to treat the whole package as equally urgent when the calendar says otherwise.
Now look at why this is moving now. The expanded 301 hearings are a broadening of the tool beyond its original China focus, and the timing sits deliberately ahead of the 24 July Section 122 expiry. Strictly speaking, Section 122 and Section 301 are different authorities with different legal footing, so one expiring does not cancel the other. But the 24 July cliff concentrates every refund and restacking decision into the next month, because if Congress does not extend the 10 percent surcharge, the refund mechanics and the replacement tariff structure have to be settled before the rate lapses. The upstream driver is a calendar, not a supply event.
On layered impact, the spread is uneven and the agriculture story is the one being under-read. The named sectors, German pharma, Japanese autos, semiconductors, steel, face investigation risk that is real but slow. The China port-fee proposal, by contrast, drew an immediate warning from the Agriculture Transportation Coalition about severe harm to U.S. agricultural exports. That is the tell: a fee aimed at Chinese-built vessels lands on the bulk export trade that moves American grain and soybeans, because those commodities ride the cheapest tonnage available, much of it Chinese-built. The exporters most exposed are not the ones the policy names.
The transmission timing splits into two very different clocks. The Germany pharma hearing on 22 September is far enough out that any tariff from it lands in the fourth quarter at the earliest. The Section 122 expiry on 24 July is near-term and hard, and it governs refunds and restacking now. The China port-fee proposal has no fixed date yet, which makes it the most uncertain and the most worth a written scenario, because uncertainty is where unpriced exposure lives.
Here is the point the headlines miss, and it is the one that should reorder your list. The port fee is levied on the vessel calling at a U.S. port, and the cost does not stay with the shipowner. It is passed into the cargo, and the cargo most sensitive to a per-vessel charge is low-value, high-bulk outbound agricultural freight. So a measure framed as targeting Chinese-built ships becomes, in practice, a tax on American farmers' export channel. The Agriculture Transportation Coalition's letter is not lobbying theater, it is a description of who actually pays. If you move bulk outbound, the China port fee is your risk even if you never touch a Chinese product.
The counterview needs a line before commitments are made. Two conditions flip the conclusion. If Congress extends the Section 122 surcharge past 24 July, the near-term refund-and-restack deadline dissolves and the pressure shifts entirely to the slower 301 track. If the China port fee is finalized, the agricultural export cost equation changes regardless of the 18-partner hearings. Neither condition is visible in the sector list, and both are decided by legislative and administrative timing you do not control, so the only lever you own is a written scenario and a dated watch list.
For the compliance owner, the sequencing is the real risk, not any single tariff. The 22 September Germany pharma date feels far away, so it gets deprioritized, while the 24 July Section 122 expiry feels like someone else's problem because it is a surcharge, not a new investigation. The hazard is that both land in the same planning quarter and pull in opposite directions, one wants refund mechanics settled, the other wants comments filed. If your team treats them as separate workstreams owned by separate people, the dates collide silently and the later one loses the window. Put both on one calendar owned by one owner, because the only thing worse than missing a deadline is missing two that were visible a month apart.
↑ Back to the key points